IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. trimmed its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 26.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 172,328 shares of the company’s stock after selling 60,432 shares during the quarter. Robeco Institutional Asset Management B.V. owned 0.21% of IDEXX Laboratories worth $71,247,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of IDXX. R Squared Ltd purchased a new position in IDEXX Laboratories during the fourth quarter worth about $161,000. Perigon Wealth Management LLC boosted its position in shares of IDEXX Laboratories by 1.8% during the 4th quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company’s stock worth $632,000 after purchasing an additional 26 shares during the period. Berkshire Bank increased its holdings in IDEXX Laboratories by 5.4% in the 4th quarter. Berkshire Bank now owns 1,553 shares of the company’s stock valued at $642,000 after purchasing an additional 80 shares during the last quarter. Union Bancaire Privee UBP SA purchased a new stake in IDEXX Laboratories in the fourth quarter valued at approximately $1,544,000. Finally, E Fund Management Hong Kong Co. Ltd. lifted its stake in IDEXX Laboratories by 182.8% during the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 164 shares of the company’s stock worth $68,000 after purchasing an additional 106 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

IDXX has been the topic of several research analyst reports. StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, November 28th. Leerink Partners assumed coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They set an “outperform” rating and a $500.00 price target on the stock. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Barclays dropped their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Finally, Stifel Nicolaus reduced their target price on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a report on Thursday, October 10th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $517.29.

Insider Activity

In related news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the transaction, the director now directly owns 905 shares of the company’s stock, valued at $380,498.20. This trade represents a 27.54 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 2.11% of the company’s stock.

IDEXX Laboratories Trading Up 0.2 %

NASDAQ IDXX opened at $418.75 on Thursday. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $583.39. The firm has a 50 day moving average of $423.92 and a two-hundred day moving average of $455.05. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $34.29 billion, a PE ratio of 40.38, a price-to-earnings-growth ratio of 3.63 and a beta of 1.36.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.69 by $0.11. The firm had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. IDEXX Laboratories’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.53 earnings per share. As a group, research analysts expect that IDEXX Laboratories, Inc. will post 10.44 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.